Home › Companies › RIGEL PHARMACEUTICALS INC. › 2024-2025
Compiled from SEC Form N-PX filings and RIGEL PHARMACEUTICALS INC.’s Form 8-K, filed 2025-05-23 (Item 5.07 on EDGAR). Page generated 02 October 2026.
Explore RIGEL PHARMACEUTICALS INC. in the interactive database Compare manager voting policies
These tallies are RIGEL PHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2025-05-23 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Outcome |
|---|---|---|---|---|---|---|
| Elect Director: Kamil Ali-Jackson | 10,542,422 | -- | 199,277 | 227,808 | 2,860,105 | Majority: yes |
| Elect Director: Jane Wasman | 10,380,140 | -- | 202,144 | 387,223 | 2,860,105 | Majority: yes |
| Approval of the Amended 2018 Plan The Company's stockholders approved the Amended 2018 Plan. | 6,856,776 | 3,591,569 | 521,162 | -- | 2,860,105 | Majority: yes |
| Say-on-Pay The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement. | 9,388,816 | 993,913 | 586,778 | -- | 2,860,105 | Majority: yes |
Source: RIGEL PHARMACEUTICALS INC., Form 8-K, filed with the SEC on 2025-05-23 — read the filing on EDGAR.
Each item below shows how the 169 asset managers that disclosed a RIGEL PHARMACEUTICALS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of RIGEL PHARMACEUTICALS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Combines 6 wordings of this item as funds reported it.
90% Majority: yes · of votes cast
RIGEL PHARMACEUTICALS INC.’s own tally for this item (“Say-on-Pay The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement.”): 9,388,816 for, 993,913 against, per its Form 8-K filed 2025-05-23 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 17,710,216 outstanding shares: 53.0% for, 6% against (59% of the company cast a for/against vote).
The 169 asset managers below cast 97% of the shares they voted on this item FOR (9,855,548 for, 314,008 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 1,562,478 | 4,380 | 0 | 0 | For |
| ARMISTICE CAPITAL, LLC | 1,237,013 | 0 | 0 | 0 | For |
| Soleus Capital Management, L.P. | 1,125,601 | 0 | 0 | 0 | For |
| Vanguard | 1,036,157 | 0 | 0 | 0 | For |
| State Street | 901,445 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 409,282 | 0 | 0 | 0 | For |
| Fidelity | 373,061 | 0 | 0 | 0 | For |
| SEI | 342,481 | 0 | 0 | 0 | For |
| Hillsdale Investment Management Inc. | 191,364 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 160,000 | 0 | 0 | 0 | For |
| MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST | 160,000 | 0 | 0 | 0 | For |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 156,059 | 0 | 0 | 0 | For |
| Northern Trust | 135,781 | 0 | 0 | 0 | For |
| Charles Schwab | 132,674 | 0 | 0 | 0 | For |
| Lazard | 0 | 131,575 | 0 | 0 | Against |
| Renaissance | 128,874 | 0 | 0 | 0 | For |
| Nuveen | 115,218 | 0 | 0 | 0 | For |
| TIAA | 115,218 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 114,310 | 0 | 0 | 0 | For |
| MARSHALL WACE, LLP | 92,503 | 0 | 0 | 0 | For |
| Voya | 91,838 | 0 | 0 | 0 | For |
| ZACKS INVESTMENT MANAGEMENT | 90,147 | 0 | 0 | 0 | For |
| Connor, Clark & Lunn Investment Management Ltd. | 72,509 | 0 | 0 | 0 | For |
| Equitable | 61,567 | 0 | 0 | 0 | For |
| STATE OF WISCONSIN INVESTMENT BOARD | 57,070 | 0 | 0 | 0 | For |
Showing the 25 largest of 169 asset managers. See all 169 in the interactive database.
Combines 2 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
RIGEL PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Jane Wasman”): 10,380,140 for, 387,223 withheld, per its Form 8-K filed 2025-05-23 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 17,710,216 outstanding shares: 59% for, 2% withheld (61% of the company cast a for/withheld vote).
The 59 asset managers below cast 99% of the shares they voted on this item FOR (3,650,123 for, 39,111 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,003,468 | 0 | 0 | 0 | For |
| BlackRock | 860,256 | 0 | 0 | 0 | For |
| Fidelity | 363,082 | 0 | 0 | 0 | For |
| State Street | 275,324 | 0 | 0 | 0 | For |
| SEI | 171,118 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 160,000 | 0 | 0 | 0 | For |
| TIAA | 115,218 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 114,310 | 0 | 0 | 0 | For |
| Charles Schwab | 66,337 | 0 | 0 | 0 | For |
| Equitable | 30,094 | 31,473 | 0 | 0 | Against |
| BRIDGEWAY FUNDS INC | 46,520 | 0 | 0 | 0 | For |
| TARGET PORTFOLIO TRUST | 42,600 | 0 | 0 | 0 | For |
| Voya | 36,921 | 0 | 0 | 0 | For |
| Zacks Trust | 34,902 | 0 | 0 | 0 | For |
| MFS | 33,396 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 30,035 | 0 | 0 | 0 | For |
| Dimensional | 28,804 | 0 | 0 | 0 | For |
| Lincoln Financial | 24,236 | 0 | 0 | 0 | For |
| CLEARWATER INVESTMENT TRUST | 23,424 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 23,213 | 0 | 0 | 0 | For |
| Brighthouse | 7,690 | 0 | 8,866 | 0 | Abstain |
| ALPS ETF Trust | 13,328 | 0 | 0 | 0 | For |
| Legg Mason | 11,580 | 0 | 0 | 0 | For |
| Lazard | 10,837 | 0 | 0 | 0 | For |
| Global X | 10,358 | 0 | 0 | 0 | For |
Showing the 25 largest of 59 asset managers. See all 59 in the interactive database.
Combines 2 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
RIGEL PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Kamil Ali-Jackson”): 10,542,422 for, 227,808 withheld, per its Form 8-K filed 2025-05-23 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 17,710,216 outstanding shares: 60% for, 1% withheld (61% of the company cast a for/withheld vote).
The 59 asset managers below cast 99.1% of the shares they voted on this item FOR (3,657,761 for, 31,473 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,003,468 | 0 | 0 | 0 | For |
| BlackRock | 860,256 | 0 | 0 | 0 | For |
| Fidelity | 363,082 | 0 | 0 | 0 | For |
| State Street | 275,324 | 0 | 0 | 0 | For |
| SEI | 171,118 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 160,000 | 0 | 0 | 0 | For |
| TIAA | 115,218 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 114,310 | 0 | 0 | 0 | For |
| Charles Schwab | 66,337 | 0 | 0 | 0 | For |
| Equitable | 30,094 | 31,473 | 0 | 0 | Against |
| BRIDGEWAY FUNDS INC | 46,520 | 0 | 0 | 0 | For |
| TARGET PORTFOLIO TRUST | 42,600 | 0 | 0 | 0 | For |
| Voya | 36,921 | 0 | 0 | 0 | For |
| Zacks Trust | 34,902 | 0 | 0 | 0 | For |
| MFS | 33,396 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 30,035 | 0 | 0 | 0 | For |
| Dimensional | 28,804 | 0 | 0 | 0 | For |
| Lincoln Financial | 24,236 | 0 | 0 | 0 | For |
| CLEARWATER INVESTMENT TRUST | 23,424 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 23,213 | 0 | 0 | 0 | For |
| Brighthouse | 7,690 | 0 | 8,866 | 0 | Abstain |
| ALPS ETF Trust | 13,328 | 0 | 0 | 0 | For |
| Legg Mason | 11,580 | 0 | 0 | 0 | For |
| Lazard | 10,837 | 0 | 0 | 0 | For |
| Global X | 10,358 | 0 | 0 | 0 | For |
Showing the 25 largest of 59 asset managers. See all 59 in the interactive database.
Combines 2 wordings of this item as funds reported it.
66% Majority: yes · of votes cast
RIGEL PHARMACEUTICALS INC.’s own tally for this item (“Approval of the Amended 2018 Plan The Company's stockholders approved the Amended 2018 Plan.”): 6,856,776 for, 3,591,569 against, per its Form 8-K filed 2025-05-23 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 17,710,216 outstanding shares: 39% for, 20% against (59% of the company cast a for/against vote).
The 59 asset managers below cast 75% of the shares they voted on this item FOR (2,764,297 for, 924,937 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,003,468 | 0 | 0 | 0 | For |
| BlackRock | 860,256 | 0 | 0 | 0 | For |
| Fidelity | 363,082 | 0 | 0 | 0 | For |
| State Street | 0 | 275,324 | 0 | 0 | Against |
| SEI | 171,118 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 0 | 160,000 | 0 | 0 | Against |
| TIAA | 115,218 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 0 | 114,310 | 0 | 0 | Against |
| Charles Schwab | 66,337 | 0 | 0 | 0 | For |
| Equitable | 30,094 | 31,473 | 0 | 0 | Against |
| BRIDGEWAY FUNDS INC | 0 | 46,520 | 0 | 0 | Against |
| TARGET PORTFOLIO TRUST | 42,600 | 0 | 0 | 0 | For |
| Voya | 0 | 36,921 | 0 | 0 | Against |
| Zacks Trust | 34,902 | 0 | 0 | 0 | For |
| MFS | 0 | 33,396 | 0 | 0 | Against |
| QUANTITATIVE MASTER SERIES LLC | 30,035 | 0 | 0 | 0 | For |
| Dimensional | 0 | 28,804 | 0 | 0 | Against |
| Lincoln Financial | 0 | 24,236 | 0 | 0 | Against |
| CLEARWATER INVESTMENT TRUST | 0 | 23,424 | 0 | 0 | Against |
| Direxion Shares ETF Trust | 0 | 23,213 | 0 | 0 | Against |
| Brighthouse | 0 | 7,690 | 8,866 | 0 | Abstain |
| ALPS ETF Trust | 0 | 13,328 | 0 | 0 | Against |
| Legg Mason | 0 | 11,580 | 0 | 0 | Against |
| Lazard | 0 | 10,837 | 0 | 0 | Against |
| Global X | 10,358 | 0 | 0 | 0 | For |
Showing the 25 largest of 59 asset managers. See all 59 in the interactive database.
93% fund support · no official result
The 59 asset managers below cast 93% of the shares they voted on this item FOR (3,426,043 for, 263,191 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,003,468 | 0 | 0 | 0 | For |
| BlackRock | 860,256 | 0 | 0 | 0 | For |
| Fidelity | 363,082 | 0 | 0 | 0 | For |
| State Street | 275,324 | 0 | 0 | 0 | For |
| SEI | 0 | 171,118 | 0 | 0 | Against |
| Delaware/Macquarie | 160,000 | 0 | 0 | 0 | For |
| TIAA | 115,218 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 114,310 | 0 | 0 | 0 | For |
| Charles Schwab | 0 | 66,337 | 0 | 0 | Against |
| Equitable | 61,567 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 46,520 | 0 | 0 | 0 | For |
| TARGET PORTFOLIO TRUST | 42,600 | 0 | 0 | 0 | For |
| Voya | 36,921 | 0 | 0 | 0 | For |
| Zacks Trust | 34,902 | 0 | 0 | 0 | For |
| MFS | 33,396 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 30,035 | 0 | 0 | 0 | For |
| Dimensional | 28,804 | 0 | 0 | 0 | For |
| Lincoln Financial | 24,236 | 0 | 0 | 0 | For |
| CLEARWATER INVESTMENT TRUST | 23,424 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 23,213 | 0 | 0 | 0 | For |
| Brighthouse | 7,690 | 0 | 8,866 | 0 | Abstain |
| ALPS ETF Trust | 13,328 | 0 | 0 | 0 | For |
| Legg Mason | 11,580 | 0 | 0 | 0 | For |
| Lazard | 0 | 10,837 | 0 | 0 | Against |
| Global X | 0 | 10,358 | 0 | 0 | Against |
Showing the 25 largest of 59 asset managers. See all 59 in the interactive database.
Ranked by the number of RIGEL PHARMACEUTICALS INC. shares each manager voted on the most widely held ballot item of the 2024-2025 meeting, shown as a share of the 17,710,216 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | BlackRock | 8.85% |
| 2 | ARMISTICE CAPITAL, LLC | 6.98% |
| 3 | Soleus Capital Management, L.P. | 6.36% |
| 4 | Vanguard | 5.85% |
| 5 | State Street | 5.09% |
| 6 | GEODE CAPITAL MANAGEMENT, LLC | 2.31% |
| 7 | Fidelity | 2.11% |
| 8 | SEI | 1.93% |
| 9 | Hillsdale Investment Management Inc. | 1.08% |
| 10 | Delaware/Macquarie | 0.90% |
Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).
| Holder | % outstanding | Disclosure |
|---|---|---|
| BlackRock | 9.78% | 13F |
| Morgan Stanley | 8.68% | 13F |
| Armistice Capital, LLC | 7.23% | 13G |
| Vanguard Group | 5.80% | 13F |
| State Street | 3.60% | 13F |
| Geode Capital | 2.32% | 13F |
| Renaissance Technologies | 1.14% | 13F |
| Northern Trust | 0.80% | 13F |
| Invesco | 0.76% | 13F |
| Charles Schwab | 0.37% | 13F |
Percentages above are of 17,710,216 shares outstanding, as reported by RIGEL PHARMACEUTICALS INC. on its Form 10-K dated 2024-12-31 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from RIGEL PHARMACEUTICALS INC.’s 10-K dated 2024-12-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.
At RIGEL PHARMACEUTICALS INC.'s shareholder meeting held 2025-05-22, in the 2024-2025 proxy season, 169 asset managers reported how they voted in their SEC Form N-PX filings, covering 910 separate fund positions. Their filings are grouped here into 5 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of the Company's named executive officers… — FOR was 90% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: RIGEL PHARMACEUTICALS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2025-05-23.
RIGEL PHARMACEUTICALS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.